Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €358.04 EUR
Change Today -16.44 / -4.39%
Volume 1.8K
IDP On Other Exchanges
Symbol
Exchange
Mexico
Frankfurt
As of 1:37 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

biogen inc (IDP) Snapshot

Open
€370.70
Previous Close
€374.48
Day High
€374.50
Day Low
€355.62
52 Week High
03/23/15 - €447.80
52 Week Low
05/7/14 - €199.71
Market Cap
84.2B
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
235.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN INC (IDP)

biogen inc (IDP) Details

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

7,550 Employees
Last Reported Date: 02/4/15
Founded in 1985

biogen inc (IDP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen inc (IDP) Key Developments

Biogen Idec Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Biogen Idec Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $2,554,963,000 against $2,129,751,000 a year ago. Income from operations was $1,117,875,000 against $671,348,000 a year ago. Income before income tax expense and equity in loss of investee, net of tax was $1,102,889,000 against $665,747,000 a year ago. Net income attributable to the company was $822,541,000 against $479,956,000 a year ago. Diluted earnings per share attributable to the company were $3.49 against $2.02 a year ago. Non-GAAP earnings per diluted share were $3.82 against $2.47 a year ago. Non-GAAP net income attributable to the company was $900.2 million against $586.9 million a year ago.

Biogen Announces New Data from the ATTAIN Study Which Demonstrate the Long-Term Safety and Efficacy of PLEGRIDY over Three Years in People with Relapsing-Remitting Multiple Sclerosis

Biogen announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY (peginterferon beta-1a) over three years in people with relapsing-remitting multiple sclerosis (RRMS). The interim results from the first year of ATTAIN, a two-year extension study of the Phase 3 ADVANCE study, show the benefits of continued PLEGRIDY treatment on clinical outcomes and further define its safety profile. The study results will be presented at the 67th American Academy of Neurology's (AAN) Annual Meeting in Washington, DC. The safety and tolerability of PLEGRIDY observed in all patients enrolled in the ATTAIN study were in line with the profile demonstrated in the ADVANCE study. The most common AEs reported were injection site reactions and flu-like symptoms, the majority of which were mild or moderate. The rate of neutralizing antibodies was one percent after three years. Efficacy Results: The efficacy data from the first year of the ATTAIN study represent patients who have three years of continuous, fixed-dose treatment with PLEGRIDY. The efficacy findings are consistent with the Phase 3 ADVANCE study and continue to support PLEGRIDY’s robust efficacy over time: Patients with RRMS who were administered PLEGRIDY subcutaneously every two weeks over the three year period maintained positive efficacy results on clinical outcomes including annualized relapse rate (ARR), the proportion of patients suffering a relapse, and the proportion of patients with 24-week confirmed disability progression. PLEGRIDY also showed continued efficacy over the three year period across important MRI measures: number of gadolinium (Gd+) enhanced lesions, new T1-hypointense lesions, and new or newly enlarging T2-hyperintense lesions. Additionally, the results from the study included a post-hoc analysis on NEDA outcomes, which in ATTAIN were defined as no evidence of disease activity on clinical and MRI measures, indicating no relapses and no onset of 24-week disability progression, no Gd+ lesions, and no new or enlarging T2-hyperintense lesions. The percentage of patients in the intent-to-treat (ITT) population who achieved NEDA were 34.8% in year one and 54.3% in year two of the ADVANCE study, and 48.7% in year one of the ATTAIN study, demonstrating continued efficacy over a period of three years.

Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Biogen announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study to demonstrate remyelination (the formation of new myelin on axons) following an inflammatory injury in humans. These data will be presented at the 67th Annual Meeting of the American Academy of Neurology (AAN) in Washington, DC. The new data demonstrate a statistically significant improvement in recovery of optic nerve conduction latency (time for a signal to travel from the retina to the brain’s visual cortex), as measured by the primary endpoint full-field visual evoked potential (FF-VEP), among anti-LINGO-1-treated participants at the last study visit (week 32), as compared to placebo. Results from a sub study of multifocal VEP (mfVEP) are consistent with the FF-VEP findings. These data supplement the top-line, 24-week RENEW results reported by Biogen in January 2015. Results from RENEW show improved latency recovery, as measured by the primary endpoint, FF-VEP, among anti-LINGO-1 participants, compared with placebo. Per-protocol participants showed a 34% improvement of 7.55 milliseconds in optic nerve conduction latency at week 24, compared with placebo (p=0.05). Further latency recovery was observed at the last study visit (week 32), with a statistically significant 41% improvement of 9.13 milliseconds, compared with placebo (p=0.01). Together, the data demonstrate evidence of treatment effect with continuous improvement observed 12 weeks following the last study dose (week 20). In a pre-specified analysis, 53% of anti-LINGO-1 participants demonstrated normal or nearly normal (within 10% of the normal, unaffected eye) FF-VEP latency, compared with 26% of participants in the placebo group. SYNERGY, a separate Phase 2 clinical trial studying the impact of anti-LINGO-1 on improving and slowing disease progression among participants with relapsing forms of MS (both relapsing-remitting and secondary progressive), is ongoing with results anticipated in 2016. The primary SYNERGY endpoint is the composite change in neuro-physical and/or cognitive function, and the trial is designed to last for 84 weeks. It also includes several imaging biomarkers to investigate the potential for anti-LINGO-1 to repair MS brain lesions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €358.04 EUR -16.44

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $65.02 USD -1.05
Bristol-Myers Squibb Co $65.16 USD -0.64
Celgene Corp $114.72 USD -3.99
Medtronic PLC $76.21 USD -1.40
Novo Nordisk A/S kr394.00 DKK +3.70
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
Price/Earnings 29.0x
Price/Sales 9.3x
Price/Book 8.1x
Price/Cash Flow 25.4x
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.